EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
about
Detection of HBV Covalently Closed Circular DNAEarly experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan AfricaChronic hepatitis B virus infection and preterm labor(birth) in pregnant women-An updated systematic review and meta-analysis.A Comparison of Hepatitis B Virus Infection in HIV-infected and HIV-uninfected Participants Enrolled in a Multi-National Clinical Trial: HPTN 052.HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data MiningTenofovir Alafenamide: A Review in Chronic Hepatitis B.New antivirals for the treatment of chronic hepatitis B.Immune Evasion Strategies during Chronic Hepatitis B and C Virus InfectionHepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen.HIV-hepatitis B virus co-infection: epidemiology, pathogenesis, and treatment.Hepatitis B Virus-Hepatitis D Virus mother-to-child co-transmission: A retrospective study in a developed country.Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease.Ratios of T-helper 2 Cells to T-helper 1 Cells and Cytokine Levels in Patients with Hepatitis B.Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels.Enrichment of Ly6C(hi) monocytes by multiple GM-CSF injections with HBV vaccine contributes to viral clearance in a HBV mouse model.Overexpression of microRNA let-7 correlates with disease progression and poor prognosis in hepatocellular carcinoma.Hepatitis B in patients with hematological diseases: An update.Mucosal-associated invariant T (MAIT) cells are more activated in chronic hepatitis B, but not depleted in blood: reversal by antiviral therapy.Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection.Epidemiology of chronic hepatitis B virus in Ireland using routinely collected surveillance and administrative data, 2004-2014.Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan.Unmet Needs in Clinical and Basic Hepatitis B Virus Research.Negative Correlation of Serum Hepatitis B Surface Antigen and Hepatitis B e Antigen Levels with the Severity of Liver Inflammation in Treatment-naïve Patients with Chronic Hepatitis B Virus Infection.Performance verification and comparison of TianLong automatic hypersensitive hepatitis B virus DNA quantification system with Roche CAP/CTM system.Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.Nucleos(t)ide Analogue Treatment for Adult Patients with HBeAg-positive Chronic Infection with Genotype C Hepatitis B Virus: A Nationwide Real-life Study.Combining GP73 with liver stiffness measurements: A proof-of-concept for non-invasive fibrosis assessment in antiviral-naïve HBV patients.Nucleoside analogs treatment delay the onset of hepatocellular carcinoma in patients with HBV-related cirrhosis.Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis.Serum hepatitis B surface antigen levels predict insignificant fibrosis and non-cirrhosis in hepatitis B e antigen positive patients with normal or mildly elevated alanine transaminase levels.Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy.Can We Trust Safety of Tenofovir Disoproxil in Patients with Decompensated Cirrhosis?Baracle® vs Baraclude® for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety.Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues.miR-185 Inhibits Fibrogenic Activation of Hepatic Stellate Cells and Prevents Liver Fibrosis.Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
P2860
Q32183310-6C49A262-F0FB-46C0-835E-9F24A94F97ACQ33815159-A879E727-CB58-45C3-9C44-05CD70B39E5CQ38603535-CBD8AB47-8F20-4112-9FC8-BFB4A9304365Q38657651-7C68A9CE-915E-4CF3-A2DD-DA55FB24D811Q38657888-69901F51-D15B-4AA8-8F2F-D848F17234EEQ39298139-933BFEA7-D54A-4485-A16E-F4307CDB391FQ39315990-6439CB06-88B3-4536-B76B-F19E3AE9AA6AQ39327457-80954048-AA5D-440D-89D2-85F2F8002004Q39414876-CEB36F4B-9747-498C-8BB6-81F9E44AC289Q39425755-A9382393-326A-4F64-8DAC-27E3E4BA4924Q40073563-4D661C8F-F299-450B-9EC6-9059AB457457Q40084913-18279815-F15F-45E9-B44D-A0AA1B2F1D86Q40106389-44F0808B-B663-48F7-B535-839FFA7B7E95Q40122998-029348CC-B379-44F3-8074-A094413CB4C7Q40126197-68E952CD-755B-43B8-95C8-8EB4A0BB6559Q41390560-70259C06-7392-42EE-9258-27228C83FACCQ41690596-619B759F-44E9-4EFB-BA90-561EF5990CD6Q41926537-C5F7165C-CD29-463B-BADC-0669A9FF56E8Q41927231-9FA59750-AA13-46BF-940E-000E1080C6A3Q41931198-B466AC09-AB49-497E-A319-69A3B6A42751Q41986565-A3BBF5F1-F52D-405E-9547-14B0AE0D0452Q42374435-15A04F43-0CAA-4929-BF8B-7D945B0239B8Q45323572-26E391AD-E2B4-47F0-AB28-8D11F5324BF0Q45324374-63BAAF33-004C-4CDD-B90F-5FF1D829353EQ45324577-65EAB420-3518-4E06-954A-8C8F58D6FBA5Q45324890-7A5DFE26-7027-4045-BB78-66AF4571FC3BQ45325498-F5B87BD2-B1E3-4023-8A25-3E0974D70AF1Q45326295-2DCD5B0B-3DC0-43FC-862F-B205779D82D3Q45326378-430115B7-365A-4693-805A-E3C813B071D2Q45326396-40A1314E-A8D2-418B-BEA0-A53354B4B540Q45873545-C5ECC505-EAF4-40F1-8993-BA6F27E52E63Q47117446-C30D205C-FC03-447D-8E30-4F3070CD047FQ47128327-9F1EE572-FD02-4E7E-9DC4-87AA59795181Q47135430-668291A4-69CC-4DB0-9D6F-3797906CB251Q47142298-B4F3F471-84C6-4DAA-A6C3-554A6B133C52Q47146218-E9C2D6A4-3C53-4725-AEA2-BCC1065B1A49Q47151413-D4FD5CC2-A03D-4A76-8923-AF819E0C0573Q47153893-BC5F0A8A-4927-4970-A349-17C0DC1DFC94Q47155517-028C08D6-1B9B-4661-B370-FC71A6B6B11BQ47163223-3328AA25-8F91-4437-95CB-D4EE754103D8
P2860
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
@en
type
label
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
@en
prefLabel
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
@en
P1476
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
@en
P2093
European Association for the Study of the Liver
European Association for the S ...... ress: easloffice@easloffice.eu
P304
P356
10.1016/J.JHEP.2017.03.021
P577
2017-03-27T00:00:00Z